MYIA
SRPT icon

Mount Yale Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Mount Yale Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-472
Closed -$8.07K – 1482
2025
Q2 		$8.07K Buy
+472
New +$20.1K ﹤0.01% 1164
2018
Q4 		– Sell
-501
Closed -$72K – 707
2018
Q3 		$72K Sell
501
-2
-0.4% -$273 0.01% 535
2018
Q2 		$66K Hold
503
– – 0.01% 581
2018
Q1 		$37K Buy
+503
New +$33.5K 0.01% 678

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Mount Yale Investment Advisors's SRPT Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 472 shares — an estimated $8.07K sold.

Mount Yale Investment Advisors first reported a position in SRPT in Q1 2018 and held it in 4 quarters. The position peaked at $72K in Q3 2018. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 472 Sarepta Therapeutics shares in Q3 2025, an estimated $8.07K.
  • Mount Yale Investment Advisors first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 4 quarters.
  • Mount Yale Investment Advisors's Sarepta Therapeutics position peaked at $72K in Q3 2018.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.